Quantum BioPharma Appoints Multiple Sclerosis Expert Dr. Jack Antel as Clinical Advisor for Lucid-MS Development

Quantum BioPharma Ltd. has appointed Dr. Jack Antel, a world-renowned multiple sclerosis expert and Professor of Neurology at McGill University, as clinical advisor to support the development of Lucid-21-302, the company's patented investigational drug designed to inhibit demyelination in MS. Dr. Antel, who brings extensive expertise with over 450 published articles and recognition as a recipient of the National Multiple Sclerosis Society and American Academy of Neurology's Dystel Award, will guide the design of efficacy trials as Quantum advances Lucid-MS into Phase 2 studies. His appointment strengthens the clinical advisory team that includes Dr. Peter Stys, Professor of Neurosciences at the University of Calgary, who continues to serve as clinical advisor for the program.

The addition of Dr. Antel represents a significant step forward for Quantum BioPharma's multiple sclerosis program as the company prepares for more advanced clinical testing. Lucid-MS is a patented new chemical entity that has demonstrated the ability to prevent and reverse myelin degradation in preclinical models, targeting the underlying mechanism of multiple sclerosis. Myelin degradation is the central pathological process in MS where the protective covering of nerve fibers deteriorates, leading to the neurological symptoms characteristic of the disease. The company's focus on developing treatments for challenging neurodegenerative disorders positions this appointment as strategically important for advancing their lead compound through the clinical development pathway.

Quantum BioPharma maintains its commitment to building a portfolio of innovative assets for treating neurodegenerative and metabolic disorders, with Lucid-MS representing their most advanced program in the multiple sclerosis space. The company operates through its wholly owned subsidiary, Lucid Psycheceuticals Inc., which focuses specifically on the research and development of Lucid-MS. Additional information about the company's developments is available through their newsroom at https://ibn.fm/QNTM. This strategic appointment comes at a critical juncture as the company transitions from preclinical validation to human clinical trials, where Dr. Antel's expertise in multiple sclerosis clinical trial design will be invaluable for optimizing study protocols and endpoints.

The significance of this appointment extends beyond the immediate clinical advisory role, reflecting Quantum BioPharma's broader strategy to leverage world-class scientific expertise in advancing their neurodegenerative disorder pipeline. With multiple sclerosis affecting approximately 2.8 million people worldwide and current treatments primarily focusing on symptom management and disease modification rather than addressing the fundamental demyelination process, Lucid-MS represents a potentially novel approach to treatment. The company's parallel activities include maintaining strategic investments through its wholly owned subsidiary FSD Strategic Investments Inc., though the primary focus remains on advancing their therapeutic pipeline for conditions with significant unmet medical needs.